Unither Pharmaceuticals

Unither Pharmaceuticals is a global leader in contract manufacturing for liquid pharmaceuticals, with a dominant position in Blow-Fill-Seal (BFS) technology producing over 5 billion doses annually. The company operates nine production sites across four continents, offering comprehensive CDMO services from development to regulatory support and commercial production. With over 2,500 employees, Unither serves a broad client base from startups to large pharma, focusing on therapeutic areas like ophthalmology, ENT, and respiratory diseases. Its business model is built on flexible partnerships including contract manufacturing, co-development, and out-licensing of turnkey products.

World leader in Blow-Fill-Seal (BFS) technology for sterile single-dose units. Also possesses multi-dose, spray, stick-pack, and vial manufacturing capabilities. Integrated platform includes formulation development, analytical services, regulatory support, and commercial manufacturing.

Unither competes in the global CDMO market, with direct competitors including other large players like Catalent, Lonza, and Recipharm that offer liquid manufacturing. Its primary differentiation is its declared world leadership in high-volume Blow-Fill-Seal (BFS) technology, a specialized niche with high barriers to entry. It also competes with regional CDMOs and the internal manufacturing capabilities of large pharmaceutical companies.